<html><head></head><body><h1>Trimethoprim and Polymyxin B</h1><ul class="ddc-anchor-links"><li>Uses</li>
<li>Contraindications</li>
<li>Dosage</li>
<li>Storage</li>
<li>Interactions</li>
<li>Warnings</li>
<li>Pregnancy</li>
<li>Patient education</li></ul><h2>Pronunciation</h2><p>(trye METH oh prim &amp; pol i MIKS in bee)</p><h2>Index Terms</h2><ul><li>Polymyxin B and Trimethoprim</li></ul><h2>Dosage Forms</h2><p>Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p><p>Solution, ophthalmic: Trimethoprim 1 mg and polymyxin B sulfate 10,000 units per 1 mL (10 mL)</p><p>Polytrim®: Trimethoprim 1 mg and polymyxin B sulfate 10,000 units per 1 mL (10 mL) [contains benzalkonium chloride] </p><h2>Brand Names: U.S.</h2><ul><li>Polytrim</li></ul><h2>Pharmacologic Category</h2><ul><li>Antibiotic, Ophthalmic</li></ul><h3>Absorption</h3><p>Trimethoprim and polymyxin B are systemically absorbed following ophthalmic installation. Peak concentrations were trimethoprim 0.03 mcg/mL and polymyxin B 1 unit/mL.</p><h2 class="ddc-anchor-offset" id="uses">Use: Labeled Indications</h2><p>Treatment of surface ocular bacterial conjunctivitis and blepharoconjunctivitis</p><h2 class="ddc-anchor-offset" id="contraindications">Contraindications</h2><p>Hypersensitivity to trimethoprim, polymyxin B, or any component of the formulation</p><h2 class="ddc-anchor-offset" id="dosage">Dosing: Adult</h2><p><b>Conjunctivitis, blepharoconjunctivitis:</b> Ophthalmic: Instill 1 drop in affected eye(s) every 3 hours (maximum: 6 doses per day) for 7-10 days; has also been used 4 times daily for 5-7 days (Williams, 2013; <i>The Wills Eye Manual</i>, 2004) </p><h2>Dosing: Geriatric</h2><p>Refer to adult dosing.</p><h2>Dosing: Pediatric</h2><p><b>Conjunctivitis, blepharoconjunctivitis: </b>Infants ≥2 months, Children, and Adolescents: Ophthalmic: Instill 1 drop in eye(s) every 3 hours; maximum daily dose: 6 doses/<b>day </b>for 7 to 10 days; in children and adolescents, 4 times daily dosing for 5 to 7 days has also been used (Williams 2013)</p><h2>Administration</h2><p>Avoid contamination of the applicator tip.</p><h2 class="ddc-anchor-offset" id="storage">Storage</h2><p>Store at 15°C to 25°C (59°F to 77°F); protect from light.</p><h2 class="ddc-anchor-offset" id="interactions">Drug Interactions</h2><p>Amantadine: Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine. <i> Monitor therapy</i></p><p>Amodiaquine: Trimethoprim may enhance the neutropenic effect of Amodiaquine. Trimethoprim may increase the serum concentration of Amodiaquine. <i> Avoid combination</i></p><p>Angiotensin II Receptor Blockers: Trimethoprim may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Monitor therapy</i></p><p>Angiotensin-Converting Enzyme Inhibitors: Trimethoprim may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Monitor therapy</i></p><p>AzaTHIOprine: Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine. <i> Monitor therapy</i></p><p>Bacitracin (Systemic): Polymyxin B may enhance the nephrotoxic effect of Bacitracin (Systemic). <i> Avoid combination</i></p><p>BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Avoid combination</i></p><p>BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Monitor therapy</i></p><p>Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.<i> Monitor therapy</i></p><p>Cefazedone: May enhance the nephrotoxic effect of Polymyxin B.<i> Monitor therapy</i></p><p>Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Avoid combination</i></p><p>Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate. <i> Monitor therapy</i></p><p>Dapsone (Systemic): Trimethoprim may increase the serum concentration of Dapsone (Systemic). Dapsone (Systemic) may increase the serum concentration of Trimethoprim. <i> Monitor therapy</i></p><p>Dapsone (Topical): Trimethoprim may enhance the adverse/toxic effect of Dapsone (Topical). More specifically, trimethoprim may increase the risk for hemolysis <i> Monitor therapy</i></p><p>Digoxin: Trimethoprim may increase the serum concentration of Digoxin. <i> Monitor therapy</i></p><p>Dofetilide: Trimethoprim may increase the serum concentration of Dofetilide. <i> Avoid combination</i></p><p>Eplerenone: Trimethoprim may enhance the hyperkalemic effect of Eplerenone. <i> Monitor therapy</i></p><p>Fosphenytoin: May decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Fosphenytoin. Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Consider therapy modification</i></p><p>Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Monitor therapy</i></p><p>LamiVUDine: Trimethoprim may increase the serum concentration of LamiVUDine. <i> Monitor therapy</i></p><p>Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for <i>Pneumocystis jirovecii</i> pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.<i> Avoid combination</i></p><p>Mecamylamine: Polymyxin B may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Avoid combination</i></p><p>Memantine: Trimethoprim may enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Trimethoprim may increase the serum concentration of Memantine. Memantine may increase the serum concentration of Trimethoprim. <i> Monitor therapy</i></p><p>Mercaptopurine: Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine. <i> Monitor therapy</i></p><p>MetFORMIN: Trimethoprim may increase the serum concentration of MetFORMIN. <i> Monitor therapy</i></p><p>Methotrexate: Trimethoprim may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).<i> Consider therapy modification</i></p><p>Methoxyflurane: May enhance the nephrotoxic effect of Polymyxin B.<i> Avoid combination</i></p><p>Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.  Management: If possible, avoid concomitant use of neuromuscular-blocking agents and polymyxin B. If concomitant use cannot be avoided, monitor for deeper, prolonged neuromuscular-blocking effects (eg, respiratory paralysis) in patients receiving this combination.<i> Consider therapy modification</i></p><p>Phenytoin: Trimethoprim may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Trimethoprim.  Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Consider therapy modification</i></p><p>PRALAtrexate: Trimethoprim may increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of trimethoprim. Monitor for decreased pralatrexate levels with discontinuation of trimethoprim.<i> Monitor therapy</i></p><p>Procainamide: Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.  Management: Consider alternatives to trimethoprim-containing regimens to avoid this interaction. If coadministered, monitor for increased procainamide adverse effects (increased QTc) if trimethoprim is initiated/dose increased.<i> Consider therapy modification</i></p><p>Pyrimethamine: May enhance the adverse/toxic effect of Trimethoprim.<i> Monitor therapy</i></p><p>Repaglinide: CYP2C8 Inhibitors (Weak) may increase the serum concentration of Repaglinide. <i> Monitor therapy</i></p><p>RifAMPin: May decrease the serum concentration of Trimethoprim.<i> Monitor therapy</i></p><p>Sapropterin: Trimethoprim may decrease the serum concentration of Sapropterin. Specifically, trimethoprim may decrease tissue concentrations of tetrahydrobiopterin. <i> Monitor therapy</i></p><p>Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Consider therapy modification</i></p><p>Spironolactone: Trimethoprim may enhance the hyperkalemic effect of Spironolactone. <i> Monitor therapy</i></p><p>Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Consider therapy modification</i></p><p>Varenicline: Trimethoprim may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Monitor therapy</i></p><h2>Adverse Reactions</h2><p>The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p><p>Frequency not defined:</p><p>Dermatologic: Circumocular rash</p><p>Ophthalmic: Burning sensation of eyes, eyelid edema, eye pruritus, eye redness (increased), lacrimation, stinging of eyes</p><h2 class="ddc-anchor-offset" id="warnings">Warnings/Precautions</h2><p>See individual agents.</p><h2 class="ddc-anchor-offset" id="pregnancy">Pregnancy Risk Factor
C

Pregnancy Considerations</h2><p>Adverse events have been observed with trimethoprim in animal reproduction studies; animal reproduction studies have not been conducted with polymyxin B. See individual agents. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease potential exposure to the fetus (Samples 1988).</p><h2 class="ddc-anchor-offset" id="patient-education">Patient Education</h2><p><b>What is this drug used for?</b></p><p>• It is used to treat eye infections.</p><p><b>All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:</b></p><p>• Burning</p><p>• Stinging</p><p>• Itching</p><p><b>WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:</b></p><p>• Vision changes</p><p>• Eye pain</p><p>• Severe eye irritation</p><p>• Eyelid swelling</p><p>• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.</p><p><b>Note:</b> This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.</p><p><b>Consumer Information Use and Disclaimer:</b> This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.</p><h2>More about polymyxin b / trimethoprim ophthalmic</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>24 Reviews</li>
<li>Drug class: ophthalmic anti-infectives</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Polymyxin b and trimethoprim Ophthalmic &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Conjunctivitis, Bacterial</li>
<li>Blepharoconjunctivitis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>